2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Abstract

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patient s’ risk stratification. Although beneficial effects of radioiodine are undisputed in high -risk patients, controversy remains in intermediate-risk and some low-risk pati ents. Since the last consensus on post-surgical use of RAI in DTC patients, new retr ospective data and results of prospective randomized trials have been published, w hich have allowed the development of a new European Thyroid Association (ETA) stateme nt for the indications of post-surgical RAI therapy in DTC. Questions about which pati ents are candidates for RAI therapy, which activities of RAI can be used, and which mod alities of pre-treatment patient preparation should be used are addressed in the present guidelines.

Keywords

• differentiated thyroid cancer
• radioiodine
• treatment
• indications